PURPOSE: Few studies to date have evaluated factors associated with the development of radiation pneumonitis (RP) in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), especially in patients treated with contemporary radiation techniques. These patients represent a unique group owing to the often large radiation target volumes within the mediastinum and to the potential to receive several lines of chemotherapy that add to pulmonary toxicity for relapsed or refractory disease. Our objective was to determine the incidence and clinical and dosimetric risk factors associated with RP in lymphoma patients treated with intensity modulated radiation therapy (IMRT) at a single institution. METHODS AND MATERIALS: We retrospectively reviewed clinical charts and radiation records of 150 consecutive patients who received mediastinal IMRT for HL and NHL from 2009 through 2013. Clinical and dosimetric predictors associated with RP according to Radiation Therapy Oncology Group (RTOG) acute toxicity criteria were identified in univariate analysis using the Pearson χ(2) test and logistic multivariate regression. RESULTS: Mediastinal radiation was administered as consolidation therapy in 110 patients with newly diagnosed HL or NHL and in 40 patients with relapsed or refractory disease. The overall incidence of RP (RTOG grades 1-3) was 14% in the entire cohort. Risk of RP was increased for patients who received radiation for relapsed or refractory disease (25%) versus those who received consolidation therapy (10%, P=.019). Several dosimetric parameters predicted RP, including mean lung dose of >13.5 Gy, V20 of >30%, V15 of >35%, V10 of >40%, and V5 of >55%. The likelihood ratio χ(2) value was highest for V5 >55% (χ(2) = 19.37). CONCLUSIONS: In using IMRT to treat mediastinal lymphoma, all dosimetric parameters predicted RP, although small doses to large volumes of lung had the greatest influence. Patients with relapsed or refractory lymphoma who received salvage chemotherapy and hematopoietic stem cell transplantation were at higher risk for symptomatic RP.
PURPOSE: Few studies to date have evaluated factors associated with the development of radiation pneumonitis (RP) in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), especially in patients treated with contemporary radiation techniques. These patients represent a unique group owing to the often large radiation target volumes within the mediastinum and to the potential to receive several lines of chemotherapy that add to pulmonary toxicity for relapsed or refractory disease. Our objective was to determine the incidence and clinical and dosimetric risk factors associated with RP in lymphomapatients treated with intensity modulated radiation therapy (IMRT) at a single institution. METHODS AND MATERIALS: We retrospectively reviewed clinical charts and radiation records of 150 consecutive patients who received mediastinal IMRT for HL and NHL from 2009 through 2013. Clinical and dosimetric predictors associated with RP according to Radiation Therapy Oncology Group (RTOG) acute toxicity criteria were identified in univariate analysis using the Pearson χ(2) test and logistic multivariate regression. RESULTS: Mediastinal radiation was administered as consolidation therapy in 110 patients with newly diagnosed HL or NHL and in 40 patients with relapsed or refractory disease. The overall incidence of RP (RTOG grades 1-3) was 14% in the entire cohort. Risk of RP was increased for patients who received radiation for relapsed or refractory disease (25%) versus those who received consolidation therapy (10%, P=.019). Several dosimetric parameters predicted RP, including mean lung dose of >13.5 Gy, V20 of >30%, V15 of >35%, V10 of >40%, and V5 of >55%. The likelihood ratio χ(2) value was highest for V5 >55% (χ(2) = 19.37). CONCLUSIONS: In using IMRT to treat mediastinal lymphoma, all dosimetric parameters predicted RP, although small doses to large volumes of lung had the greatest influence. Patients with relapsed or refractory lymphoma who received salvage chemotherapy and hematopoietic stem cell transplantation were at higher risk for symptomatic RP.
Authors: M L Hernando; L B Marks; G C Bentel; S M Zhou; D Hollis; S K Das; M Fan; M T Munley; T D Shafman; M S Anscher; P A Lind Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-01 Impact factor: 7.038
Authors: Anne-Marie Charpentier; Tatiana Conrad; Jenna Sykes; Angela Ng; Rachel Zhou; Amy Parent; Catherine Coolens; Richard W Tsang; Mary K Gospodarowicz; Alexander Sun; David C Hodgson Journal: Pract Radiat Oncol Date: 2013-09-16
Authors: Peter M Petersen; Marianne C Aznar; Anne K Berthelsen; Annika Loft; Deborah A Schut; Maja Maraldo; Mirjana Josipovic; Thomas L Klausen; Flemming L Andersen; Lena Specht Journal: Acta Oncol Date: 2014-07-15 Impact factor: 4.089
Authors: Tim Illidge; Lena Specht; Joachim Yahalom; Berthe Aleman; Anne Kiil Berthelsen; Louis Constine; Bouthaina Dabaja; Kavita Dharmarajan; Andrea Ng; Umberto Ricardi; Andrew Wirth Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-01 Impact factor: 7.038
Authors: Lena Specht; Joachim Yahalom; Tim Illidge; Anne Kiil Berthelsen; Louis S Constine; Hans Theodor Eich; Theodore Girinsky; Richard T Hoppe; Peter Mauch; N George Mikhaeel; Andrea Ng Journal: Int J Radiat Oncol Biol Phys Date: 2013-06-18 Impact factor: 7.038
Authors: M J Stuart; N S Chao; S J Horning; R M Wong; R S Negrin; L J Johnston; J A Shizuru; G D Long; K G Blume; K E Stockerl-Goldstein Journal: Biol Blood Marrow Transplant Date: 2001 Impact factor: 5.742
Authors: Khinh Ranh Voong; Kelli McSpadden; Chelsea C Pinnix; Ferial Shihadeh; Valerie Reed; Mohammad R Salehpour; Isidora Arzu; He Wang; David Hodgson; John Garcia; Michalis Aristophanous; Bouthaina S Dabaja Journal: Radiat Oncol Date: 2014-04-15 Impact factor: 3.481
Authors: J S Stenehjem; K B Smeland; K Murbraech; H Holte; S Kvaløy; T Wethal; C E Kiserud; M B Lund Journal: Bone Marrow Transplant Date: 2016-12-19 Impact factor: 5.483
Authors: Chelsea C Pinnix; Laura Cella; Therese Y Andraos; Zeina Ayoub; Sarah A Milgrom; Jillian Gunther; Sonali Thosani; Christine Wogan; Manuel Conson; Vittoria D'Avino; Yasuhiro Oki; Michelle Fanale; Hun J Lee; Sattva Neelapu; Luis Fayad; Frederick Hagemeister; M Alma Rodriguez; Loretta J Nastoupil; Yago Nieto; Wei Qiao; Roberto Pacelli; Bouthaina Dabaja Journal: Int J Radiat Oncol Biol Phys Date: 2018-03-14 Impact factor: 7.038
Authors: Alexander N Hanania; Walker Mainwaring; Yohannes T Ghebre; Nicola A Hanania; Michelle Ludwig Journal: Chest Date: 2019-04-15 Impact factor: 9.410
Authors: Chelsea C Pinnix; Andrew Wirth; Sarah A Milgrom; Therese Y Andraos; Michalis Aristophanous; Mary Pham; Donald Hancock; Ethan B Ludmir; Jillian R Gunther; Michelle A Fanale; Yasuhiro Oki; Loretta Nastoupil; Hubert H Chuang; N George Mikhaeel; Bouthaina S Dabaja Journal: Leuk Lymphoma Date: 2018-04-04
Authors: Giuseppe Palma; Serena Monti; Vittoria D'Avino; Manuel Conson; Raffaele Liuzzi; Maria Cristina Pressello; Vittorio Donato; Joseph O Deasy; Mario Quarantelli; Roberto Pacelli; Laura Cella Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-07 Impact factor: 7.038